One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

Frank T. Watkins net worth and biography

Frank Watkins Biography and Net Worth

Director of Shockwave Medical

Jay T. Watkins is a businessperson who founded Gynecare, Inc. (New Jersey) and Origin Medsystems, Inc. and who has been the head of 7 different companies. Currently, Mr. Watkins is Chairman for Reflexion Medical, Inc., Chairman of Tissium SA, Managing Director at Sonder Capital Management LLC and Chairman for C2 Therapeutics, Inc. Jay T. Watkins is also on the board of 8 other companies. Mr. Watkins previously occupied the position of President for Heart Rhythm Technologies, Inc., Consultant at McKinsey & Co., Inc., Managing Director at De Novo Ventures, Chairman of ReCor Medical, Inc., President of Guidant Compass Group, President-Minimally Invasive Surgery Group at Guidant Corp., Principal at Microgenics Corp. and Director at Gynecare, Inc. (New Jersey). Mr. Watkins received an undergraduate degree from Stanford University and an MBA from Harvard Business School.

What is Frank T. Watkins' net worth?: The estimated net worth of Frank T. Watkins is at least $1.49 million as of March 6th, 2024. Mr. Watkins owns 4,532 shares of Shockwave Medical stock worth more than $1,488,173 as of April 19th. This net worth evaluation does not reflect any other investments that Mr. Watkins may own. Learn More about Frank T. Watkins' net worth.
How do I contact Frank T. Watkins?: The corporate mailing address for Mr. Watkins and other Shockwave Medical executives is 5403 Betsy Ross Drive, Santa Clara CA, 95054. Shockwave Medical can also be reached via phone at (877) 775-4846 and via email at [email protected]. Learn More on Frank T. Watkins' contact information.
Has Frank T. Watkins been buying or selling shares of Shockwave Medical?: Frank T. Watkins has not been actively trading shares of Shockwave Medical during the last quarter. Most recently, Frank T. Watkins sold 2,000 shares of the business's stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $253.65, for a transaction totalling $507,300.00. Following the completion of the sale, the director now directly owns 4,532 shares of the company's stock, valued at $1,149,541.80. Learn More on Frank T. Watkins' trading history.
Who are Shockwave Medical's active insiders?: Shockwave Medical's insider roster includes Colin Cahill (Director), Laura Francis (Director), Douglas Godshall (CEO), Antoine Papiernik (Director), Trinh Phung (VP), Dan Puckett (CFO), Maria Sainz (Director), Frank Watkins (Director), and Isaac Zacharias (Insider). Learn More on Shockwave Medical's active insiders.
Are insiders buying or selling shares of Shockwave Medical?: In the last year, insiders at the sold shares 47 times. They sold a total of 221,744 shares worth more than $52,184,011.04. The most recent insider tranaction occured on March, 26th when Director Laura Francis sold 1,500 shares worth more than $450,000.00. Insiders at Shockwave Medical own 3.4% of the company. Learn More about insider trades at Shockwave Medical.
Information on this page was last updated on 3/26/2024.

Frank T. Watkins Insider Trading History at Shockwave Medical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/6/2024	Sell	2,000	$253.65	$507,300.00	4,532
2/6/2024	Sell	2,000	$231.76	$463,520.00	4,532
1/8/2024	Sell	2,000	$198.99	$397,980.00	4,532
11/20/2023	Sell	3,000	$173.35	$520,050.00	1,532
10/20/2023	Sell	3,000	$202.70	$608,100.00	1,532
9/20/2023	Sell	3,000	$209.23	$627,690.00	1,532
8/21/2023	Sell	3,000	$219.29	$657,870.00	1,532
7/20/2023	Sell	3,000	$267.17	$801,510.00	1,532
6/20/2023	Sell	3,000	$287.52	$862,560.00	1,532
5/22/2023	Sell	3,000	$278.32	$834,960.00	3,796
4/20/2023	Sell	3,000	$261.43	$784,290.00	3,796
3/20/2023	Sell	3,000	$200.67	$602,010.00	3,796
2/21/2023	Sell	3,000	$193.19	$579,570.00	3,796
1/20/2023	Sell	3,000	$176.29	$528,870.00	3,796
1/9/2023	Sell	10,000	$203.73	$2,037,300.00	3,796
11/17/2022	Sell	3,000	$244.44	$733,320.00	3,796
10/20/2022	Sell	3,000	$267.14	$801,420.00	6,796
9/20/2022	Sell	3,000	$290.09	$870,270.00	9,796
8/22/2022	Sell	3,000	$291.87	$875,610.00	12,796
7/20/2022	Sell	3,000	$206.44	$619,320.00	15,796
6/21/2022	Sell	3,000	$161.43	$484,290.00	17,802
5/20/2022	Sell	3,000	$162.98	$488,940.00	20,802
4/20/2022	Sell	3,000	$206.01	$618,030.00	23,802
3/21/2022	Sell	3,000	$175.18	$525,540.00
2/22/2022	Sell	3,000	$143.86	$431,580.00
1/20/2022	Sell	3,000	$148.41	$445,230.00
12/29/2021	Sell	20,000	$176.25	$3,525,000.00
11/16/2021	Sell	2,000	$208.41	$416,820.00
10/19/2021	Sell	2,000	$201.37	$402,740.00
9/21/2021	Sell	2,008	$216.76	$435,254.08
8/17/2021	Sell	2,000	$185.67	$371,340.00
7/20/2021	Sell	2,000	$170.20	$340,400.00	75,678
6/16/2021	Sell	2,000	$192.65	$385,300.00	76,549
5/19/2021	Sell	2,000	$159.46	$318,920.00	82,860
4/20/2021	Sell	2,000	$138.35	$276,700.00	86,952
3/16/2021	Sell	2,000	$114.98	$229,960.00	90,769
2/16/2021	Sell	2,000	$132.27	$264,540.00	94,593
1/19/2021	Sell	2,000	$141.24	$282,480.00	98,773
12/16/2020	Sell	8,000	$96.86	$774,880.00	111,974

Frank T. Watkins Buying and Selling Activity at Shockwave Medical

Shockwave Medical Company Overview

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

Today's Range

Now: $328.37

$327.39

$328.38

50 Day Range

MA: $282.20

$230.90

$329.64

2 Week Range

Now: $328.37

$157.00

$331.58

Volume

979,771 shs

Average Volume

958,491 shs

Market Capitalization

$12.28 billion

P/E Ratio

84.85

Dividend Yield

N/A

Beta

0.92

Strange new buyer driving up gold

From Stansberry Research | Ad